BioAge Initiates Phase 2a Trial of BGE-117 in Elderly Patients with Unexplained Anemia

BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target aging to treat severe diseases, today announced that it has commenced a Phase 2a clinical trial of BGE-117, an activator of hypoxia signaling, for unexplained anemia of aging (UAA).